Standardized cannabis in multiple sclerosis: a case report by Hornby, Paul & Sharma, Manju
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Cases Journal
Open Access Case Report
Standardized cannabis in multiple sclerosis: a case report
Paul Hornby*1 and Manju Sharma2
Address: 1Department of Medical Cannabis Research, The Green Cross Society of BC, 2127, Kingsway, Vancouver, B.C., V5N 2T4, Canada and 
2Department of Pathology and Laboratory Medicine, Heather Pavilion, Vancouver, General Hospital, Vancouver, B.C., Canada
Email: Paul Hornby* - paul@hedron.ca; Manju Sharma - manjusharma49@gmail.com
* Corresponding author    
Abstract
A 52 year old female suffering from severe progressive multiple sclerosis was administered
quantifiable amounts of standardized cannabis and monitored over the period of one year, while
providing daily pain charts and records of her condition. An average daily intake of 500 mg of
Tetrahydrocannabinol as cannabis was required to achieve a desired quality of life.
Introduction
Multiple Sclerosis (MS) is a difficult disease both to diag-
nose and to treat. Diagnosis often requires multiple visits
to the physician and it may take years before MS is diag-
nosed, typed and treated.
There is no cure for MS. Treatment is based on powerful
immune system suppressants, mainly steroids and various
types of Interferon, although others may be used as well.
In addition, many types of medications including anti-
cholinergics, antispasmodics, benzodiazepines and opi-
ates are used to manage the muscle spasms, bladder
incontinence issues and nerve pain that may be associated
with MS. They do however prevent recurrence and slow
progression of the illness. Prevention of MS through vita-
min D supplementation is an intriguing possibility.
In the study described here we trace the cannabis use of an
MS patient over the course of one year. High Pressure Liq-
uid Chromatography (HPLC) was performed to quantify
cannabis. The subject made significant improvement with
better pain control, decreased muscle spasms and general
quality of life. The case described here is one of many
observed at the Green Cross Society of B.C.
Case presentation
The subject in this study, a 52-year-old female, is a mem-
ber of the Green Cross Society which is a non-profit,
organization, dedicated to supplying quality controlled,
standardized cannabis to its qualified members. The par-
ticipant involved in this year-long study was chosen pri-
marily because she had an attentive, full-time, caregiver,
who had tracked her illness since its beginning in the late
1970's. It was the caregiver that first noticed that cannabis
was beneficial in relieving her symptoms. This however,
was sometime after the disease was diagnosed.
Initially she was subjected to a 10-day regimen of ACTH,
plus various muscle relaxants and anxiolytics. Intermit-
tent ACTH treatment occurred until 1985 when Magnetic
Resonance Imaging confirmed her diagnosis with MS. She
then began daily injections of Copaxone, which gave ben-
efits including reduction of muscle spasms and a degree of
pain management. In addition, she would also smoke
cannabis to further alleviate symptoms.
Initial symptoms had included numbness of the right side
of the lip, and a depressed gag reflex that made swallow-
ing difficult. These symptoms had been present for a dec-
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ade prior to the suspicion and diagnosis of MS. In 1983,
she began experiencing extreme pain in her lower lumbar
region that radiated to her left foot, affecting her ability to
walk. When she first came to the Society in 2007, she com-
plained of chronic pain, tremor, difficulty in walking and
a severe constant pain in her left foot.
Through the Green Cross Society, the subject received
advice on the best cannabis strain selection for her symp-
toms plus options on means of administration and dos-
age regimens. For the following year she ingested
cannabis that had been tested for concentrations of the
most abundant cannabinoids including Delta-9 Tetrahy-
drocannabinol (THC), Cannabidiol (CBD) and Cannabi-
nol (CBN). Her caregiver provided daily (email) pain
charts, plus ingested medications, and a description of the
subject's general well being throughout the study.
Discussion
Results were assessed through daily dialogue with the sub-
ject's caregiver, review of accumulated pain charts, plus
the subject's testimony. An almost immediate improve-
ment was seen in the patient's condition when she began
administering the standardized oral preparations. Pain
scores were reduced from an 8 - 10 to 1 - 2 over the period
of the first month during which time the optimal dosing
regimen was established (Figures 1 and 2: example pain
charts). Greatest benefit for pain and tremor was achieved
consuming 6-8, 50 mg capsules per day, dosing at 4-hour
intervals. The subject also consumed an average of 4-6
cannabis cigarettes per day, for breakthrough pain and/or
mood enhancement. Measurement of the mean THC con-
centration of these cigarettes was 172 ± 26 n = 30, that
would equate to a dosage of 25 mg of THC per cigarette
(0.5 grams per cigarette with roughly 70% loss to atmos-
phere) [1], adding another 125 mg to her daily consump-
tion, totaling between 400 and 500 mg per day of THC.
The average relative amounts of CBD and CBN are
roughly 3% of that found for THC. A significant improve-
ment in pain levels, tremor and general well being were
observed. Functionally, the patient went from a state of
virtual incapacitation to one where she can dress, go for
walks and do some gardening: a dramatic improvement
over the course of one year.
The presence of CBD and CBN, although claiming no psy-
choactive effect, appear to modulate the binding of THC
to its receptor and thus alter the efficacy of the prepara-
tion. The relative ratio of these three cannabinoids is
determined by the specific strain of cannabis. Over the
course of the study year it was found that the subject expe-
rienced optimal relief with strains containing relatively
high CBD to THC ratio of 4-6%, a high THC concentra-
tion and relatively low CBN amount. Observations made
with the study subject and, indeed, verified day-to-day at
the Society is that those managing chronic pain prefer
these ratios.
The seemingly high amounts of THC (approximately 500
mg/day) required by the subject to manage her symptoms
are often observed with persons of her genealogy (Scot-
tish). An earlier publication on the effects of standardized
cannabis and chronic pain management describes a simi-
lar tolerant response [2]. A phenomenon often witnessed
at the Society is persons with Celtic genealogy require 3 -
5 five times greater dosage than those of Middle European
or other descent.
The only observed unwanted side effects were seen when
the strain used in the oral capsules was changed to one
that did not provide the same pain or anti-tremor relief as
the strain provided at an earlier time. Simply put, there
was some discomfort experienced in changing strains.
Since the subject was receiving the medication by mail,
from time to time, she would run out of the oral prepara-
tion at which time her symptoms would worsen to their
pre-regimen state within days. Recent tests of liver func-
tions proved normal.
Conclusions
The established non-toxicity of cannabis and non-addic-
tive properties [3] make it an excellent candidate for treat-
ing the symptoms of numerous illnesses. The case
described here is one of many observed at the Green Cross
Society of B.C.
Footnote HPLC
High pressure liquid chromatography, using a Hewlett-
Packard (Agilent) 1090 Series II binary pumping system
with a 79883a diode array detector, with primary absorb-
ance at 219 nm, was conducted. Mobile phase at 1 ml/
min was isocratic with 14% aqueous (1:25:974 phos-
phoric acid: acetonitrile: distilled water) and 86% organic
phase (acetonitrile). The column was a Zorbax C18
reverse phase 4.6 mm × 25 cm. Samples were prepared by
the method modified from Health Canada for the prepa-
ration of hemp samples for HPLC analysis [4]. Calibration
curves were run for a number of commercial standards
(Sigma) and averages made. 0.1 gram of dry (dryness
determination appendix 1) cannabis was suspended in 10
ml THF and sonicated for 3 minutes then passed through
a 0.45 micron nylon syringe filter into a 1 ml HPLC sam-
ple vial. Under these conditions suitable chromatography
is achieved for the three most abundant cannabinoids
present in the samples provided to the Society's members.
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Example pain chart from early in the study Figure 1
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Example pain chart from study mid-point Figure 2
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nol; THF: tetrahydrofuran; HPLC: high performance
liquid chromatography.
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